OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform.
Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash.
Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application for Tzield (teplizumab-mzwv), allowing its use to delay stage 3 type 1 diabetes (T1D) onset in children as young as one year diagnosed with stage 2 T1D.
Merck & Co (MSD) and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI enterprise transformation.
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.
Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia and Xgeva, respectively.
Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their supplemental biologics licence application (sBLA) for perioperative Padcev (enfortumab vedotin-ejfv) combined with the PD-1 inhibitor Keytruda (pembrolizumab) for muscle-invasive bladder cancer (MIBC).
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company.
UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.
Merck & Co (MSD) has received the European Commission (EC) approval for Enflonsia (clesrovimab), indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their initial RSV season.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.